Context Therapeutics Showcases CTIM-76 at ASCO Annual Meeting
Context Therapeutics Inc. is making significant strides in oncology research with its groundbreaking clinical trial of CTIM-76, a bispecific antibody designed to target a specific protein found in various solid tumors. This Phase 1 trial is particularly focused on patients suffering from ovarian, endometrial, and testicular cancers, representing a critical advance in cancer treatment options.
Details of the CTIM-76 Clinical Trial
During the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Context Therapeutics presented a Trial in Progress poster detailing their Phase 1 clinical study evaluating CTIM-76. This clinical trial is structured as an open-label study involving dose escalation and expansion phases aimed at assessing the safety and effectiveness of CTIM-76 in patients with CLDN6-positive cancers.
The trial is set to enroll approximately 70 participants, focusing on carefully evaluating several key metrics: safety, tolerability, pharmacokinetics, and overall anti-tumor activity. These metrics will be assessed through various measures including the overall response rate and duration of response, which are vital for understanding how well this treatment might work. This dual approach not only helps in assessing efficacy but also establishes a clearer understanding of the drug's safety profile.
Recent Milestones and Future Plans
As of early 2025, Context Therapeutics revealed that they have already dosed their first patient and are currently enrolling patients in cohort 3 of the study. With seven active trial sites in operation across the United States, the company continues to expand its efforts in gathering crucial data. The initial data from this study is anticipated to be shared in the first half of 2026, marking a pivotal moment in the development of CTIM-76.
The poster presented at ASCO included essential information about the study, such as the title, "A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors," along with its abstract number TPS2685. This highlights the company’s commitment to transparency and keeping the medical community informed about their research progress.
What Sets CTIM-76 Apart?
CTIM-76 has garnered attention due to its unique mechanism of action. As a CLDN6 x CD3 T cell engaging bispecific antibody, it holds the potential for acting against specific tumor types while minimizing the risk of immune-related side effects. This innovative approach is expected to facilitate more personalized treatment plans for patients, enhancing their chances of favorable outcomes in previously hard-to-treat cancers such as ovarian and endometrial cancers.
Preclinical studies have indicated promising results, suggesting that CTIM-76 may not only be effective but also easier to produce at scale compared to traditional treatments. This could potentially lead to improved access for patients who may benefit from this cutting-edge therapy.
Understanding Context Therapeutics’ Vision
Context Therapeutics Inc. (Nasdaq: CNTX) is dedicated to advancing therapies that leverage the immune system to combat solid tumors. Their strategic focus on T cell engaging bispecific antibodies, including CTIM-76, shows their commitment to overcoming the complexities of cancer treatment. Alongside CTIM-76, the company is also developing additional promising therapies like CT-95 and CT-202, targeting various cancer types with the same innovative bispecific approach.
For those interested in keeping up with the latest developments, Context Therapeutics provides resources and updates on their clinical trials through their official website. They also encourage engagement via various social media platforms, expanding their reach and community interaction.
Frequently Asked Questions
What is CTIM-76?
CTIM-76 is a bispecific antibody targeting CLDN6, aimed at treating patients with certain solid tumors, particularly ovarian and endometrial cancers.
What is the purpose of the Phase 1 trial for CTIM-76?
The trial aims to assess the safety and efficacy of CTIM-76 in patients with advanced CLDN6-positive cancers.
When can we expect initial data from the CTIM-76 trial?
Initial data from the trial is expected to be shared in the first half of 2026.
How many patients will be enrolled in the study?
Up to 70 patients are anticipated to enroll in the clinical trial.
Where can I find more information about Context Therapeutics?
More information can be found on Context Therapeutics' official website, as well as their social media pages.
